The advanced drug delivery systems (ADDS) market is expected to register a CAGR of 5.3% during the forecast period (2022-2027).
The COVID-19 pandemic is expected to have a significant effect on the market. Several studies emphasized how ADDS will help develop improved delivery systems (dosage forms) of existing therapeutic agents. For instance, in June 2020, the Chalmers University of Technology in Sweden, the University of Gothenburg, and AstraZeneca announced new pivotal research combining many promising concepts to investigate a nasal spray mRNA vaccine against COVID-19. The team is currently working on a biomimetic nanoparticle that contains both immune enhancers and a targeting protein to investigate design principles for nasal immunization. The Chalmers Innovation Office, the Chalmers Area of Advance Health Engineering, the Swedish Foundation for Strategic Research, and the Swedish Research Council contribute to the initiative (VR).
In April 2020, Bioavanta-Bosti developed a 48-hour manufacturing process using its Novochizol chitosan polysaccharide nanotechnology to encapsulate APIs or biologics for localized delivery and sustained release intra-pulmonary drug delivery formulations, which are suitable for treating COVID-19 patients. Bioavanta-Bosti also announced in 2020 that it is looking for collaborations with drug developers and clinical researchers to produce a repurposed medicine or new molecular or biological entity formulations to treat severe COVID-19 infection in the lungs. ADDS has aided in exploring new insights to identify vacant areas for future targeted distribution, and it is quickly gaining traction in the pharmaceutical sector and academic institutions.
The factors driving this market include the development of new drugs and biologics, advancements in understanding human biology and diseases, and increased R&D spending.
Advancements in several biology-oriented initiatives have opened a unique opportunity to better understand the molecular effects of human diseases and develop novel drugs and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, preventing drug degradation due to the external environment and reducing the rate of drug clearance. Advanced drugs and biologics have higher efficiency with a smaller dosage of drugs. Hence, they must be supported with advanced drug delivery systems to gain maximum efficacy.
In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and reduction in drug dosage (hence lesser need for frequent dosing). The advanced sustained release systems help target intestinal infections and others. The trend toward self-injection devices and the rapidly growing pipeline of biologics/biosimilars and auto-injectors have also recently emerged as an important class of medical devices. Many companies are focusing on the launch of new products that will contribute to market growth. For instance, in July 2019, Mylan announced the launch of its adalimumab biosimilar. Adalimumab is an injectable biologic drug that inhibits Tumor Necrosis Factor (TNF) and is indicated for treating a variety of rheumatic, dermatological, and gastroenterological autoimmune diseases. Also, Similarly, in February 2019, Sandoz, a Novartis division and a global leader in biosimilars, received European Commission approval for adalimumab biosimilar, HYRIMOZ, for subcutaneous injection in either a syringe or prefilled pen in Spain.
Duocap (capsule-in-a-capsule), electro capsule, and light up delivery monitoring technology (LDMT) are some of the controlled and targeted oral drug delivery systems which provide a new way of formulating poorly soluble compounds and monitoring the release rate of drugs. Advanced drug delivery systems are being discovered to resolve solubility problems and make the drugs more lipid-soluble. Thus, this enables them to easily cross lipid barriers in the body, eventually preventing external environment issues, such as photodegradation and pH changes, from affecting the drug and further achieving the desired concentration at the desired location to provide the maximum therapeutic effect. Thus, these developments are expected to positively impact market growth.
The oral drug delivery method is the most common and preferred drug administration route by the physician and the patient. The demand for this dosage form mostly lies in the convenience of intake and the availability of a broad window of the therapeutic index, which, in turn, lowers the possibility of toxicity and side effects. Still, its application is limited owing to the poor stability of peptides and proteins in the gastrointestinal tract.
With increasing costs and complications in developing, patenting, and marketing new drug entities, pharmaceutical companies, with simultaneous recognition of the therapeutic advantages of controlled drug delivery, are paying greater attention to developing and modifying oral release drug delivery systems. Over the last decade, oral release drug delivery systems received expansive attention owing to their flexibility, reduced dosing frequency, and better patient compliance. The factors above, in combination with the reasonable cost of oral controlled release drug delivery systems, led to the ease of market penetration.
Oral drugs constitute the largest business opportunity in the developed drug delivery system market, which is growing. The accelerated pace of advanced oral drug delivery system development is fostered by a growing market of controlled release formulations and new launches in key therapeutic areas, such as the central nervous system, cardiovascular, metabolic, and respiratory diseases. For instance, in 2020, Progenity Inc. announced positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS), the DDS capsule, which uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract. This technology is based on anatomy and is designed to resist variability in physiological conditions like pH, motility, and bacteria. The launch of such products will provide growth opportunities for the segmental market in the future.
The demand for advanced drug delivery systems such as oral thin-film drugs is rising due to their high clinical efficacy and effectiveness against diseases. For instance, SUBOXONE film has attracted substantial market attention due to its innovative offerings, which resulted in a marked shift from SUBOXONE tablet to SUBOXONE film. In March 2019, CURE Pharmaceutical expanded its oral drug delivery product line, creating the CURE form, which includes CURE film, an advanced oral thin film. The new line adds CURE pod chewable and emulsions to meet the increased demand. The increase in R&D and healthcare funding by various governments is also spurring the development of advanced drug delivery systems. This segment is expected to grow due to these factors during the forecast period.
North America currently dominates the global advanced drug delivery systems market owing to the better adoption of improved drug delivery solutions and follow-up of advanced treatment approaches in healthcare. The United States (US) is the largest market in the region.
The growing inclination toward self-administration of drugs, increasing innovations in injectable drug delivery systems, the high adoption rate of new healthcare technologies, and the high prevalence of chronic diseases are the primary drivers for the US advanced drug delivery systems market. Chronic diseases and conditions are on the rise. Heart disease is a leading cause of death that burdens people, communities, healthcare providers, and systems. Nearly half of all adults in the United States have some cardiovascular disease. According to the American Cancer Society, nearly 2 million new cancer cases are expected to be diagnosed, and some 609,000 people will likely die from cancer in the US in 2022. Moreover, according to the American Diabetes Association data, in 2019, 37.5 million Americans had diabetes. Diabetes cases are expected to increase. Thus, the demand for advanced drug delivery systems is expected to grow with a steeply rising patient population.
The advanced drug delivery systems market is moderately competitive. Some major players in this market are Boston Scientific Corporation, Baxter International, Becton, Dickinson and Company, Kindeva Drug Delivery L.P., and others. Owing to the continuous technological advancements in the drug delivery system, there is a possibility of new entrants in the market in the coming future.
The key players have been involved in various strategic alliances such as acquisitions and collaborations and launching advanced products to secure their position in the global market. For example, in April 2020, Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of an autoinjector device for AJOVY (fremanezumab-from) injection in the United States. AJOVY is indicated for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.
This product will be delivered within 2 business days.
The COVID-19 pandemic is expected to have a significant effect on the market. Several studies emphasized how ADDS will help develop improved delivery systems (dosage forms) of existing therapeutic agents. For instance, in June 2020, the Chalmers University of Technology in Sweden, the University of Gothenburg, and AstraZeneca announced new pivotal research combining many promising concepts to investigate a nasal spray mRNA vaccine against COVID-19. The team is currently working on a biomimetic nanoparticle that contains both immune enhancers and a targeting protein to investigate design principles for nasal immunization. The Chalmers Innovation Office, the Chalmers Area of Advance Health Engineering, the Swedish Foundation for Strategic Research, and the Swedish Research Council contribute to the initiative (VR).
In April 2020, Bioavanta-Bosti developed a 48-hour manufacturing process using its Novochizol chitosan polysaccharide nanotechnology to encapsulate APIs or biologics for localized delivery and sustained release intra-pulmonary drug delivery formulations, which are suitable for treating COVID-19 patients. Bioavanta-Bosti also announced in 2020 that it is looking for collaborations with drug developers and clinical researchers to produce a repurposed medicine or new molecular or biological entity formulations to treat severe COVID-19 infection in the lungs. ADDS has aided in exploring new insights to identify vacant areas for future targeted distribution, and it is quickly gaining traction in the pharmaceutical sector and academic institutions.
The factors driving this market include the development of new drugs and biologics, advancements in understanding human biology and diseases, and increased R&D spending.
Advancements in several biology-oriented initiatives have opened a unique opportunity to better understand the molecular effects of human diseases and develop novel drugs and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, preventing drug degradation due to the external environment and reducing the rate of drug clearance. Advanced drugs and biologics have higher efficiency with a smaller dosage of drugs. Hence, they must be supported with advanced drug delivery systems to gain maximum efficacy.
In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and reduction in drug dosage (hence lesser need for frequent dosing). The advanced sustained release systems help target intestinal infections and others. The trend toward self-injection devices and the rapidly growing pipeline of biologics/biosimilars and auto-injectors have also recently emerged as an important class of medical devices. Many companies are focusing on the launch of new products that will contribute to market growth. For instance, in July 2019, Mylan announced the launch of its adalimumab biosimilar. Adalimumab is an injectable biologic drug that inhibits Tumor Necrosis Factor (TNF) and is indicated for treating a variety of rheumatic, dermatological, and gastroenterological autoimmune diseases. Also, Similarly, in February 2019, Sandoz, a Novartis division and a global leader in biosimilars, received European Commission approval for adalimumab biosimilar, HYRIMOZ, for subcutaneous injection in either a syringe or prefilled pen in Spain.
Duocap (capsule-in-a-capsule), electro capsule, and light up delivery monitoring technology (LDMT) are some of the controlled and targeted oral drug delivery systems which provide a new way of formulating poorly soluble compounds and monitoring the release rate of drugs. Advanced drug delivery systems are being discovered to resolve solubility problems and make the drugs more lipid-soluble. Thus, this enables them to easily cross lipid barriers in the body, eventually preventing external environment issues, such as photodegradation and pH changes, from affecting the drug and further achieving the desired concentration at the desired location to provide the maximum therapeutic effect. Thus, these developments are expected to positively impact market growth.
Key Market Trends
Oral Drug Delivery System Segment by Type to Hold the Highest CAGR
The oral drug delivery method is the most common and preferred drug administration route by the physician and the patient. The demand for this dosage form mostly lies in the convenience of intake and the availability of a broad window of the therapeutic index, which, in turn, lowers the possibility of toxicity and side effects. Still, its application is limited owing to the poor stability of peptides and proteins in the gastrointestinal tract.
With increasing costs and complications in developing, patenting, and marketing new drug entities, pharmaceutical companies, with simultaneous recognition of the therapeutic advantages of controlled drug delivery, are paying greater attention to developing and modifying oral release drug delivery systems. Over the last decade, oral release drug delivery systems received expansive attention owing to their flexibility, reduced dosing frequency, and better patient compliance. The factors above, in combination with the reasonable cost of oral controlled release drug delivery systems, led to the ease of market penetration.
Oral drugs constitute the largest business opportunity in the developed drug delivery system market, which is growing. The accelerated pace of advanced oral drug delivery system development is fostered by a growing market of controlled release formulations and new launches in key therapeutic areas, such as the central nervous system, cardiovascular, metabolic, and respiratory diseases. For instance, in 2020, Progenity Inc. announced positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS), the DDS capsule, which uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract. This technology is based on anatomy and is designed to resist variability in physiological conditions like pH, motility, and bacteria. The launch of such products will provide growth opportunities for the segmental market in the future.
The demand for advanced drug delivery systems such as oral thin-film drugs is rising due to their high clinical efficacy and effectiveness against diseases. For instance, SUBOXONE film has attracted substantial market attention due to its innovative offerings, which resulted in a marked shift from SUBOXONE tablet to SUBOXONE film. In March 2019, CURE Pharmaceutical expanded its oral drug delivery product line, creating the CURE form, which includes CURE film, an advanced oral thin film. The new line adds CURE pod chewable and emulsions to meet the increased demand. The increase in R&D and healthcare funding by various governments is also spurring the development of advanced drug delivery systems. This segment is expected to grow due to these factors during the forecast period.
North America Dominates the Market and is Believed to Follow the Same Trend Over the Forecast Period
North America currently dominates the global advanced drug delivery systems market owing to the better adoption of improved drug delivery solutions and follow-up of advanced treatment approaches in healthcare. The United States (US) is the largest market in the region.
The growing inclination toward self-administration of drugs, increasing innovations in injectable drug delivery systems, the high adoption rate of new healthcare technologies, and the high prevalence of chronic diseases are the primary drivers for the US advanced drug delivery systems market. Chronic diseases and conditions are on the rise. Heart disease is a leading cause of death that burdens people, communities, healthcare providers, and systems. Nearly half of all adults in the United States have some cardiovascular disease. According to the American Cancer Society, nearly 2 million new cancer cases are expected to be diagnosed, and some 609,000 people will likely die from cancer in the US in 2022. Moreover, according to the American Diabetes Association data, in 2019, 37.5 million Americans had diabetes. Diabetes cases are expected to increase. Thus, the demand for advanced drug delivery systems is expected to grow with a steeply rising patient population.
Competitive Landscape
The advanced drug delivery systems market is moderately competitive. Some major players in this market are Boston Scientific Corporation, Baxter International, Becton, Dickinson and Company, Kindeva Drug Delivery L.P., and others. Owing to the continuous technological advancements in the drug delivery system, there is a possibility of new entrants in the market in the coming future.
The key players have been involved in various strategic alliances such as acquisitions and collaborations and launching advanced products to secure their position in the global market. For example, in April 2020, Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of an autoinjector device for AJOVY (fremanezumab-from) injection in the United States. AJOVY is indicated for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Becton, Dickinson and Company
- Abbott Laboratories
- Baxter
- Bayer AG
- Boston Scientific Corporation
- Kindeva Drug Delivery L.P.
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- Medtronic
- Ypsomed
- Abbvie, Inc.
- Astrazeneca
Methodology
LOADING...
